收稿日期: 2023-12-10
网络出版日期: 2024-03-26
基金资助
第六批重庆市中青年医学高端人才计划资助项目
A new strategy for the management of ascites in liver cirrhosis： A long⁃term albumin treatment
Received date: 2023-12-10
Online published: 2024-03-26
文蕾 , 俞慧宏 , 凌贤龙 . 肝硬化腹水管理新策略——长期白蛋白治疗[J]. 实用医学杂志, 2024 , 40(5) : 591 -595 . DOI: 10.3969/j.issn.1006-5725.2024.05.001
Ascites is the most frequent decompensating event of cirrhosis. At present， ascites recurs at a high rate due to lack of effective management strategy and is frequently complicated with spontaneous bacterial peritonitis， hepatorenal syndrome， and liver failure， which increase the fatality rate. Albumin treatment for hepatocirrhosic ascites has a long history， but it is limited as an acute or short?term treatment. In contrast， long?term albumin administration represents a completely different treatment paradigm. Results from several recent clinical studies indicate that long?term albumin treatment can be able to modify the disease courses of some decompensated cirrhosis when albumin is given at a sufficient dose for a sufficient time. In this review， we analyze the available data acquired from long?term albumin treatments， trying to establish a secure and effective management scheme involving maximal target population， albumin dose， administration time， and standards for albumin withdrawal， and thus provide references for the clinical practice.
Key words： long?term albumin; effective albumin; ascites; decompensated cirrhosis
| 1 | GINES P， KRAG A， ABRALDES J G，et al. Liver cirrhosis［J］.Lancet， 2021， 398（10308）：1359?1376. doi:10.1016/s0140-6736(21)01374-x |
| 2 | MA C， QIAN A S， NGUYEN N H，et al. Trends in the economic burden of chronic liver diseases and cirrhosis in the United States：1996-2016［J］. Am J Gastroenterol， 2021， 116（10）：2060?2067. doi:10.14309/ajg.0000000000001292 |
| 3 | D′AMICO G， GARCIA-TSAO G， PAGLIARO L.Natural history and prognostic in Dicators of survival in cirrhosis： a systematic review of 118 studies［J］. J Hepatol， 2006，44（1）：217?231. doi:10.1016/j.jhep.2005.10.013 |
| 4 | European Association for the Study of the Liver. EASL clinical practice guidelines for the management of patients with decompensated cirrhosis［J］. J Hepatol，2018，69（2）：406?460. doi:10.1016/j.jhep.2018.08.009 |
| 5 | BIGGINS S W， ANGELI P， GARCIA-TSAO G， et al. Diagnosis， evaluation， and management of ascites， spontaneous bacterial peritonitis and hepatorenal syndrome： 2021 Practice Guidance by the American Association for the Study of Liver Diseases［J］. Hepatology， 2021，74（2）：1014?1048. doi:10.1002/hep.31884 |
| 6 | GINES P， SOLA E， ANGELI P，et al. Kamath PS. Hepatorenal syndrome［J］. Nat Rev Dis Primers， 2018，8（1）：4-23. doi:10.1038/s41572-018-0022-7 |
| 7 | DE SIMONE G， DI MASI A， ASCENZI P. Serum Albumin： A Multifaced Enzyme［J］. Int J Mol Sci， 2021，22（18）：22-35. doi:10.3390/ijms221810086 |
| 8 | BELINSKAIA D A， VORONINA P A， GONCHAROV N V. Integrative Role of Albumin： Evolutionary，Biochemical and Pathophysiological Aspects［J］. J Evol Biochem Physiol， 2021，57（6）：1419-1448. doi:10.1134/s002209302106020x |
| 9 | BERNARDI M， ANGELI P， CLARIA J， et al. Albumin in decompensated cirrhosis： new concepts and perspectives［J］. Gut，2020，69（6）：1127?1138. doi:10.1136/gutjnl-2019-318843 |
| 10 | NALDI M， BALDASSARRE M， DOMENICALI M，et al. Structural and functional integrity of human serum albumin： analytical approaches and clinical relevance in patients with liver cirrhosis［J］. J Pharm Biomed Anal， 2017，144：138?153. doi:10.1016/j.jpba.2017.04.023 |
| 11 | D’AMICO G， MARUZZELLI L， AIROLDI A，et al. Performance of the model for end-stage liver disease score for mortality prediction and the potential role of etiology［J］. J Hepatol， 2021，75（6）：1355-1366. doi:10.1016/j.jhep.2021.07.018 |
| 12 | CLARIA J， STAUBER R E， COENRAAD M J，et al. Systemic inflammation in decompensated cirrhosis：Characterization and role in acute-on-chronic liver failure［J］. Hepatology， 2016，64（4）：1249?1264. doi:10.1002/hep.28740 |
| 13 | BALDASSARRE M， NALDI M， ZACCHERINI G，et al. Determination of effective albumin in patients with decompensated cirrhosis：clinical and prognostic implications［J］. Hepatology， 2021，74（4）：2058?2073. doi:10.1002/hep.31798 |
| 14 | DAS S， MARAS J S， HUSSAIN M S，et al. Hyperoxidized albumin modulates neutrophils to induce oxidative stress and inflammation in severe alcoholic hepatitis［J］. Hepatology， 2017，65（2）：631?646. doi:10.1002/hep.28897 |
| 15 | ALCARAZ-QUILES J， CASULLERAS M， OETTL K，et al. Oxidized albumin triggers a cytokine storm in leukocytes through p38 mitogen-activated protein kinase： role in systemic inflammation in decompensated cirrhosis［J］. Hepatology， 2018，68（5）：1937?1952. doi:10.1002/hep.30135 |
| 16 | JALAN R， BERNARDI M. Effective albumin concentration and cirrhosis mortality： from concept to reality［J］. J Hepatol， 2013，59（3）：918-920. doi:10.1016/j.jhep.2013.08.001 |
| 17 | GARCIA-MARTINEZ R， CARACENI P， BERNARDI M，et al.Albumin： pathophysiologic basis of its role in the treatment of cirrhosis and its complications［J］. Hepatology， 2013，58（5）：1836?1846. doi:10.1002/hep.26338 |
| 18 | FERNANDEZ J， CLARIA J， AMOROS A，et al. Effects of albumin treatment on systemic and portal hemodynamics and systemic inflammation in patients with decompensated cirrhosis［J］. Gastroenterology， 2019，157（1）：149?162. doi:10.1053/j.gastro.2019.05.040 |
| 19 | BORTOLUZZI A， CEOLOTTO G， GOLA E，et al. Positive cardiac inotropic effect of albumin infusion in rodents with cirrhosis and ascites： molecular mechanisms［J］. Hepatology， 2013，57（1）：266?276. doi:10.1002/hep.26021 |
| 20 | CHINA L， MAINI A， SKENE S S，et al. Albumin counteracts immune-suppressive effects of lipid mediators in patients with advanced liver disease［J］. Clin Gastroenterol Hepatol， 2018，16（5）：738?747. doi:10.1016/j.cgh.2017.08.027 |
| 21 | FERNANDEZ J， ANGELI P， TREBICKA J，et al. Efficacy of albumin treatment for patients with cirrhosis and infections unrelated to spontaneous bacterial peritonitis［J］. Clin Gastroenterol Hepatol， 2019，18（4）：963?973. doi:10.1016/j.cgh.2019.07.055 |
| 22 | CASULLERAS M， FLORES-COSTA R， DURAN-GUELL M，et al. Albumin internalizes and inhibits endosomal TLR signaling in leukocytes from patients with decompensated cirrhosis［J］. Sci Transl Med， 2020，12（566）：426-439. doi:10.1126/scitranslmed.aax5135 |
| 23 | CARACENI P， RIGGIO O， ANGELI P，et al. Long-term albumin administration in decompensated cirrhosis （ANSWER）： an open-label randomised trial［J］. Lancet， 2018， 391（10138）：2417?2429. |
| 24 | CARACENI P， TUFONI M， ZACCHERINI G，et al. On-treatment serum albumin level can guide long-term treatment in patients with cirrhosis and uncomplicated ascites［J］. J Hepatol， 2021，74（2）：340?349. |
| 25 | DI PASCOLI M， FASOLATO S， PIANO S，et al. Long-term administration of human albumin improves survival in patients with cirrhosis and refractory ascites［J］. Liver Int， 2019，39（1）：98?105. doi:10.1111/liv.13968 |
| 26 | SOLA E， SOLE C， SIMON-TALERO M，et al. Midodrine and albumin for prevention of complications in patients with cirrhosis awaiting liver transplantation：A randomized placebo-controlled trial［J］. J Hepatol， 2018，69（6）：1250?1259. doi:10.1016/j.jhep.2018.08.006 |
| 27 | CHINA L， FREEMANTLE N， FORREST E，et al.A randomized trial of albumin infusions in hospitalized patients with cirrhosis［J］. N Engl J Med， 2021，384（9）：808?817. doi:10.1056/nejmoa2022166 |
| 28 | Italian Association for the Study of the Liver （AISF）. Portal hypertension and ascites： patient-and population-centered clinical practice guidelines by the Italian Association for the Study of the Liver （AISF）［J］. Dig Liver Dis， 2021， 53（9）：1089?1104. doi:10.1016/j.dld.2021.06.021 |
| 29 | VIRENDRA S， ARKA D， ROHIT M，et al. Asia?Pacifc association for study of liver guidelines on management of ascites in liver disease［J］. Hepatol Int， 2023，17（4）：792-826. doi:10.1007/s12072-023-10536-7 |
| 30 | BAI Z H， MENDEZ-SANCHEZ N， ROMEIRO F G，et al. Use of albumin infusion for cirrhosis-related complications： An international position statement［J］. JHEP Rep， 2023，5（8）：212-228. doi:10.1016/j.jhepr.2023.100785 |
| 31 | TADA S， YASUKAWA K， YATOMI Y， et al. A simple colorimetric assay to determine the concentration and proportion of human mercaptalbumin［J］. Pract Lab Med， 2022，31：e00281. doi:10.1016/j.plabm.2022.e00281 |
| 32 | FERNANDEZ J， CLARIA J， AMOROS A， et al. Effects of albumin treatment on systemic and portal hemodynamics and systemic inflammation in patients with decompensated cirrhosis［J］. Gastroenterology， 2019，157（1）：149?162. doi:10.1053/j.gastro.2019.05.040 |
| 33 | CAMPION E W， DELABRY L O， GLYNN R J. The effect of age on serum albumin level in healthy males：report from the normative aging study［J］. Gerontol， 1988，43（1）：M18?20. doi:10.1093/geronj/43.1.m18 |
/
| 〈 |
|
〉 |